Use of Campath-1H in T-cell prolymphocytic leukemia (case report and review of literature)
https://doi.org/10.17650/1818-8346-2007-0-4-84-88
Abstract
This article demonstrates case report and review of literature of successful use Campath-IH in T-cell prolymphocytic leukemia.
About the Authors
V. A. Doronin
Central Railway Clinical Hospital №2 named N.A Semashko
Russian Federation
Russian Federation
Moscow
Y. A. Krivolapov
Regional bureau of pathology
Russian Federation
Russian Federation
St.-Petersburg
N. V. Ryzhkova
Hematology Research Center of Russia
Russian Federation
Russian Federation
Moscow
O. A. Glinshikova
Hematology Research Center of Russia
Russian Federation
Russian Federation
Moscow
References
1. Catovsky D., Galetto J., Okos A. et al. Prolymphocytic leukemia of B and T cell type. Lancet 1973;2:232—4.
2. Matutes E., Brito-Bapapulle V., Swansbury J. et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991;78:3269—74.
3. Taylor A.M., Metcalfe J.A., Thick J., Mak Y.F. Leukemia and lymphoma in ataxia teleangiectasia. Blood 1996;87:423—38.
4. Rosen PJ., Said J. In: Chronic leukemias and lymphomas. Biology, pathology and clinical management. G.J Schiller (ed). Humana Press; 2003. p. 79—92.
5. Pawson R., Schulz T.F., Matutes E., Catovsky D. The human T-cell lym-photropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia. Leukemia 1997;11:1305—11.
6. Pombo de Oliveira M.S., Matutes E., Schulz T. et al. T-cell malignancies in Brazil. Clinico-pathological and molecular studies of HTLV-I-positive and-nega-tive cases. Int J Cancer 1995;60:823—7.
7. Matutes E., Garcia Talavera J., O'Brien M., Catovsky D. The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol 1986;64: 111—24.
8. Ginaldi L., Matutes E., Farahat N. et al. Differential expression of CD3 and CD7 in T-cell malignancies: a quantitative study by flow cytometry. Br J Haematol 1996;93:921—7.
9. Thick J., Metcalfe J.A., Mak Y.F. et al. Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients. Oncogene 1996;12:379—86.
10. Pekarsky Y., Hallas C., Croce C.M. The role of TCL1 in human T-cell leukemia. Oncogene 2001;20:5638—43.
11. Herling M., Khoury J.D., Washington L.T. et al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;104:328—35.
12. Hoyer K.K., French S.W., Turner D.E. et al. Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 2002;99:14392—7.
13. Virgilio L., Lazzeri C., Bichi R. et al. Deregulated expression of TCL1 causes T cell leukemia in mice. Proc Natl Acad Sci USA 1998;95:3885—9.
14. Mercieca J., Matutes E., Dearden C. et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12:2588—93.
15. Dyer M.J., Hale G., Hayhoe F.G., Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431—9.
16. Pawson R., Dyer M.J., Barge R. et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15:2667—72.
17. Dearden C.E., Matutes E., Cazin B. et al. High remission rate in T-cell prolymphocytic leukemia with CAM-PATH-1H. Blood 2001;98:1721—6.
Review
For citations:
Doronin V.A., Krivolapov Y.A., Ryzhkova N.V., Glinshikova O.A. Use of Campath-1H in T-cell prolymphocytic leukemia (case report and review of literature). Oncohematology. 2007;(4):84-88. (In Russ.) https://doi.org/10.17650/1818-8346-2007-0-4-84-88
Views:
226
Email this article 